Kilitch Drugs India Ltd approves up to ₹57 crore debt conversion and USD 14 million sale of its Ethiopian subsidiary
- The company also approved unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026.
- Consolidated Q2 revenue was ₹50.22 crore, up 14.3% YoY; net profit was ₹1.41 crore, down 82.4% YoY.
- The transaction is subject to regulatory approvals and compliance; the debt conversion is capped at ₹57 crore.
- Auditors issued an unmodified limited-review conclusion; the foreign subsidiary’s results were based on management-certified statements.